

[54] METHOD OF TREATMENT OF FIBROTIC LESIONS BY TOPICAL ADMINISTRATION OF LATHYROGENIC DRUGS**[75] Inventor:** Milos Chvapil, Tucson, Ariz.**[73] Assignee:** Bio-Products, Inc., Tucson, Ariz.**[21] Appl. No.:** 362,241**[22] Filed:** Mar. 26, 1982**[51] Int. Cl.³** A61K 9/70; A61K 31/275**[52] U.S. Cl.** 424/28; 424/304**[58] Field of Search** 424/304, 28**[56] References Cited****PUBLICATIONS**

Code of Federal Regulations 37 (7-1-82), p. 38.

Primary Examiner—Stanley J. Friedman**[57] ABSTRACT**

The disclosure deals with a method of treating fibrotic lesions related to abnormal collagen polymerization by topical administration of lathyrogenic substances, such as β -aminopropionitrile fumarate, aminoacetonitrile, D-penicillamine, into the site of the injury. The lathyrogenic drugs are administered by local injection or onto the skin and percutaneously transported into the site of the lesion. Lathyrogens, administered locally as a single drug or in combination do not produce any local or systemic toxic effects and are improving the function of the pathological fibrosis based on the accumulation of polymerized collagenous protein.

5 Claims, No Drawings